Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic CardiomyopathyStudies With Cardiac Positron Emission Tomography and Magnetic Resonance Imaging
Luuk J. Rijzewijk, MD*,
Rutger W. van der Meer, MD, PhD ,
Hildo J. Lamb, MD, PhD,
Hugo W.A.M. de Jong, PhD ,
Mark Lubberink, PhD,
Johannes A. Romijn, MD, PhD||,
Jeroen J. Bax, MD, PhD¶,
Albert de Roos, MD, PhD,
Jos W. Twisk, PhD ,
Robert J. Heine, MD, PhD*,
Adriaan A. Lammertsma, PhD,
Johannes W.A. Smit, MD, PhD|| and
Michaela Diamant, MD, PhD*,*
* Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands
Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, the Netherlands
Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
|| Department of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
¶ Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Relation of LVEDVI and the Estimate of LV Filling Pressure E/Ea
Relation between left ventricular end-diastolic volume index (LVEDVI) and the estimate of left ventricular (LV) filling pressure E/Ea in control subjects (open box, n = 24) and type 2 diabetes mellitus (T2DM) patients (solid box, n = 78). Values are mean ± SD. The LVEDVI was significantly lower in type 2 diabetes mellitus patients (p < 0.001) at similar estimates of LV filling pressure (E/Ea, p = 0.228) compatible with decreased LV compliance in T2DM patients.
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Myocardial Substrate and High-Energy Phosphate Metabolism
Myocardial fatty acid uptake (MFAU), myocardial fatty acid oxidation (MFAO), and myocardial fatty acid esterification (MFAE) (A); the metabolic rate of glucose uptake (MMRglu) (B); and phosphocreatine/adenosine triphosphate (PCr/ATP) ratio (C) in control subjects (open bars) and T2DM patients (solid bars). *p < 0.001, p < 0.01, p < 0.05. Abbreviation as in Figure 1.
|
|
|
